Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Brenus Pharma is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner, MARTIN, PAUL C, who is also designated as the busiest examiner for the portfolio. The prosecution activity is concentrated in 1 distinct art unit, which indicates a specific technical focus for the company's current filings. Because MARTIN, PAUL C is the examiner involved, they are responsible for 1 busiest examiner pending action.
The presence of 1 pending office action across 1 distinct art unit suggests a streamlined prosecution path. Since the portfolio relies on 1 distinct examiner, the applicant's strategy is dependent on the feedback and tendencies of MARTIN, PAUL C. This concentration in the Biotechnology & Pharmaceuticals sector means there is no jurisdictional or personnel variety to manage at this time. For practitioners, this means that the 1 busiest examiner pending action represents the company's current interaction with the USPTO, allowing for a focused legal approach. This specific examiner and art unit combination defines the current landscape for the company's intellectual property efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547760 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | MARTIN, PAUL C | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547760 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | MARTIN, PAUL C | 1653 | §103§112DP | Non-Final OA | — | Pending | Aug 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial